Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomised, Double-blind, Placebo-controlled Multiple Ascending Dose Study Evaluate the Efficacy and Safety of Fang yi Qing Feng Shi Granules in Subjects With Rheumatoid Arthritis

NCT02029599 is registered in ClinicalTrials.gov with Maoxiang Group Jilin Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT02029599
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02029599 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomised, Double-blind, Placebo-controlled Multiple Ascending Dose Study Evaluate the Efficacy and Safety of Fang yi Qing Feng Shi Granules in Subjects With Rheumatoid Arthritis
Lead sponsor
Maoxiang Group Jilin Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2014
Completion date
Not reported
Enrollment
240 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis